Company Overview and News

Patrys secures $3.5 million for anti-cancer therapies

Patrys Ltd (ASX:PAB) has received firm commitments from institutional and sophisticated investors to raise $3.5 million through a share placement priced at 3.4 cents.

Patrys a leading ASX gainer on brain tumour trial breakthrough

Patrys Limited (ASX:PAB) surged to a 12-month high of $0.04 on news that its drug candidate PAT‐DX1 has been shown to reduce brain tumour size in animal trials.

Patrys' shares halted

Patrys Ltd (ASX:PAB) has been granted a trading halt by the ASX this morning, pending details relating to managing its continuous disclosure obligations.

Patrys wins another U.S. patent for its unique cancer antibody

Patrys Limited (ASX:PAB) has been granted a U.S. patent for its anti-cancer candidate PAT-LM1 for use in treating colon cancer metastasis.

Patrys sits among Leading ASX % Gainers in afternoon trade

Patrys Ltd's (ASX:PAB) shares have jumped 42% to $0.027 on massive volume of over 100 million shares.

Patrys is the ASX Most Traded, but losing momentum

Patrys Ltd (ASX:PAB) is the most active stock on the ASX today, trading 87 million shares by 2pm, but its losing yesterday's momentum in the share price.

Patrys takes another gong riding near the top of the ASX Most Active

Patrys Ltd's (ASX:PAB) shares have continued to rally during the trading day, and are now up 200% at $0.012, with over 84 million shares changing hands.

Patrys' positive pre-clinical data puts it on the podium of ASX Top % Gainers

Patrys Ltd's (ASX:PAB) shares are up 75% in morning trade at $0.007, following positive pre-clinical data for its lead drug candidate PAT-DX1, a novel first-in-class drug candidate being developed to treat a range of different cancers.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...